OBJECTIVE： To compare therapeutic efficacy and safety of lobaplatin or cisplatin combined with tegafur，gimeracil and oteracil potassium in the treatment of advanced metastatic breast cancer. METHODS： A total of 160 patients with advanced metastatic breast cancer were randomly divided into observation group and control group， with 80 cases in each group. Control group was given Cisplatin injection 30 mg/m2 intravenously， every 3 weeks Tegafur，Gimeracil and Oteracil Potassium capsules 50 mg orally after meal， twice a day， for consecutive 14 days. Observation group was given Lobaplatin for injection 30 mg/m2 intravenously， every 3 weeks+Tegafur，Gimeracil and Oteracil Potassium capsules （same usage and dosage as control group）， every 3 weeks. A treatment course lasted for 3 weeks，and both groups received 2 courses. Short-term efficacies（ORR、DCR），chemotherapy effects of lymph node，lung，bone and liver， ADR and long-term efficacy were compared between 2 groups. RESULTS： After treatment， ORR（67.50％ vs. 46.25％），DCR（85.00％ vs. 66.25％），ORR of lymph node metastasis （71.43％ vs. 47.83％）， ORR of lung metastasis （60.71％ vs. 40.00％）， DCR of lung metastasis （78.57％ vs. 56.00％），ORR of bone metastasis （28.57％ vs. 16.67％）， 1-year survival rates （75.00％ vs. 52.50％） and 2-years survival rates （42.50％ vs. 17.50％） of observation group were significantly higher than control group； the incidence of chemotherapy ADR in observation group was significantly lower than control group （43.75％ vs. 70.00％）， with statistical significance （P＜0.05）. There was no statistical significance in lymph node metastasis DCR，bone tissue metastasis DCR，liver metastasis ORR and DCR，or half year sarvival rate between 2 groups（P＞0.05）. CONCLUSIONS： Compared to cisplatin combined with tegafur，gimeracil and oteracil potassium， lobaplatin combined with tegafur，gimeracil and oteracil potassium show better short-term therapeutic efficacy， therapeutic efficacy of lymph node metastasis， bone metastasis and lung metastasis，more than 1-year long-term therapeutic efficacy and safety in the treatment of advanced metastatic breast cancer.